LZ-106

LZ-106 is a **novel small-molecule anticancer agent** that is an analog of enoxacin, belonging to the quinolone family. It exhibits **potent antitumor activity** particularly against **non-small cell lung cancer (NSCLC)** in both cell culture and xenograft mouse models. Its mechanism involves **induction of apoptosis** via the mitochondrial and endoplasmic reticulum (ER)-stress apoptotic pathways, and it triggers overproduction of **reactive oxygen species (ROS)**. Both apoptosis and DNA damage response (DDR) induced by LZ-106 are dependent on ROS, and the cytotoxic effects are mediated through **P53-dependent ROS modulation**. This results in cell-cycle arrest in the G1 phase and enhanced expression of DNA damage marker proteins. The antitumor effect of LZ-106 has been validated in vitro and in vivo, and requires functional P53[1][4].